

Resource Summary Report

Generated by [kravitz2](#) on Jul 31, 2026

B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J

RRID:IMSR_JAX:005236

Type: Organism

Proper Citation

RRID:IMSR_JAX:005236

Organism Information

URL: <https://www.jax.org/strain/005236>

Proper Citation: RRID:IMSR_JAX:005236

Description: Mus musculus with name B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J from IMSR.

Species: Mus musculus

Notes: gene symbol note: T cell receptor alpha chain|T cell receptor beta chain|transgene insertion 416; Satvir S Tevethia; mutant strain|congenic strain: Tcra|Tcrb|Tg(TcraY1;TcrbY1)416Tev

Affected Gene: T cell receptor alpha chain|T cell receptor beta chain|transgene insertion 416; Satvir S Tevethia

Genomic Alteration: transgene insertion 416; Satvir S Tevethia

Catalog Number: JAX:005236

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: embryo

Organism Name: B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J

Record Creation Time: 20250513T053649+0000

Record Last Update: 20260725T044358+0000

Ratings and Alerts

No rating or validation information has been found for B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J.

No alerts have been found for B6.Cg-Tg(TcraY1.TcrbY1)416Tev/J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Shimizu K, et al. (2025) Distinct TAM subset with cross-dressing capability determines the bifurcation of tumor immunity. Cell reports, 44(6), 115800.

Kemna J, et al. (2023) IFN?? binding to extracellular matrix prevents fatal systemic toxicity. Nature immunology, 24(3), 414.

Shakiba M, et al. (2022) TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. The Journal of experimental medicine, 219(2).

Li Z, et al. (2019) Mouse CD8+NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cells. Cancer immunology, immunotherapy : CII, 68(8), 1303.

Liu D, et al. (2018) Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer. Journal of immunology research and therapy, 3(1), 115.